Dongwha Pharmaceutical

Digestive brand sold since 1897, which the company describes as Korea's first pharmaceutical product and longest-running brand; proceeds from its 128th-anniversary edition were donated to the Korean Red Cross in 2026.

Topical prescription drug for primary axillary hyperhidrosis containing sofpironium bromide, developed by Japan's Kaken Pharmaceutical; the company holds exclusive Korean rights, received MFDS approval in August 2025, and the product entered 24 general hospitals within five months of launch.

Combination treatment for mixed dyslipidemia containing pravastatin sodium 40 mg and fenofibric acid 110 mg, launched in October 2026 and taken once daily in the evening.

Pharmaceutical plant in Chungju, North Chungcheong, completed in May 2009 on an 82,500 m² site and certified to ISO 9001, ISO 14001 and ISO 45001; the research institute is in Yongin, Gyeonggi.

Spine and orthopedic implant company in the Dongwha group that received three U.S. FDA 510(k) clearances in 2026.

Launched ECCLOCK Gel, Korea's first topical prescription drug for axillary hyperhidrosis; by July 2026 it had entered 24 general hospitals.

Group company Medisay received three U.S. FDA 510(k) clearances in 2026: the Neptune 3D SA cervical cage (June), the Neptune SA cervical cage (September) and the Odys-SI sacroiliac screw (October).

Launched Pravapen Capsule, a pravastatin and fenofibric acid combination for adults at high coronary heart disease risk whose LDL cholesterol is controlled on pravastatin alone but whose triglycerides remain high and HDL cholesterol low.